Tim Maye Honored as "50 at 50" Recipient at AATB Anniversary
News related to:C5 Biomedical LLC · 2 min read
BOCA RATON, Fla., Oct. 6, 2026 /CourierPR/ -- C5 Biomedical LLC, an FDA-registered, AATB-accredited manufacturer of amniotic membrane allografts, has seen its CEO, Tim Maye, CTBS, honored as one of the "50 at 50" honorees at the 50th Anniversary Celebration of the Association for Advancing Tissue and Biologics (AATB). This recognition marks a significant milestone in Maye's 28-year career in tissue banking and biologics, during which he has held the Certified Tissue Bank Specialist (CTBS) credential since 1999.
Maye's contributions extend beyond his professional experience. He served as the chair of AATB's Standards Committee for six years, playing a pivotal role in the establishment and refinement of industry standards. His leadership and dedication were instrumental in C5 Biomedical's recent achievement of AATB accreditation in November 2025, under the standards he helped write. This accreditation underscores C5 Biomedical's commitment to maintaining the highest standards of quality and safety in the tissue banking industry.
The "50 at 50" honor recognizes 50 individuals who have significantly shaped the AATB and the broader tissue and biologics field. Maye's inclusion in this prestigious list is a testament to his extensive experience and leadership in the industry.
Maye's journey with C5 Biomedical began in 2021 when he founded the company. Since then, C5 Biomedical has grown to become a leading manufacturer of amniotic membrane allografts for use in wound care, burns, ocular, spine, orthopedic, and other surgical applications. The company's product lines include AéroGuard™, NéoGuard™, xPatch™, and iPatch™, as well as private-label allografts for distributors.
The celebration of Maye's achievement is part of AATB Congress 26, an event that brings together industry leaders to discuss advancements and challenges in the field of tissue banking and biologics. The full list of honorees is available on AATB's website, highlighting the diverse and impactful contributions of these individuals to the industry.
This recognition for Maye and C5 Biomedical underscores the company's commitment to innovation and excellence in the field of tissue banking. As Maye continues to lead the company and the industry, his work will undoubtedly continue to shape the future of tissue banking and biologics.